Dupilumab Dose Reduction Successful in Controlled AD

Continuation of standard dupilumab dosing in controlled AD can result in overtreatment and increased risks for adverse events, but a patient-centered dose reduction strategy could potentially mitigate these issues.
Medscape Medical News

source https://www.medscape.com/viewarticle/979120?src=rss